The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-β 42 by Human Microglia and Decrease Inflammatory Markers
Open accessAbstract
The use of supplements with omega-3 (ω3) fatty acids (FAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) is widespread due to proposed beneficial effects on the nervous and cardiovascular systems. Many effects of ω3 FAs are believed to be caused by down-regulation and resolution of inflammation. Alzheimer's disease (AD) is associated with inflammation mediated by microglia and astrocytes, and ω3 FAs have been proposed as potential treatments for AD. The focus of the present study is on the effects of DHA and EPA on microglial phagocytosis of the AD pathogen amyloid-β (Aβ), on secreted and cellular markers of immune activity, and on production of brain-derived neurotrophic factor (BDNF). Human CHME3 microglial cells were exposed to DHA or EPA, with or without the presence of Aβ 42 . Phagocytosis of Aβ 42 was analyzed by flow cytometry in conjunction with immunocytochemistry using antibodies to cellular proteins. Secreted proteins were analyzed by ELISA. Both DHA and EPA were found to stimulate microglial phagocytosis of Aβ 42 . Phagocytosis of Aβ 42 was performed by microglia with a predominance of M2 markers. EPA increased the levels of BDNF in the culture medium. The levels of TNF-α were decreased by DHA. Both DHA and EPA decreased the pro-inflammatory M1 markers CD40 and CD86, and DHA had a stimulatory effect on the anti-inflammatory M2 marker CD206. DHA and EPA can be beneficial in AD by enhancing removal of Aβ 42 , increasing neurotrophin production, decreasing pro-inflammatory cytokine production, and by inducing a shift in phenotype away from pro-inflammatory M1 activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Regulation of Wound Healing by Growth Factors and Cytokines
WERNER, S., & GROSE, R. (2003) · Physiological Reviews · doi:10.1152/physrev.2003.83.3.835 · Cited by 3,629 · cited 1×
“Studies on mice have shown that healing and regeneration of the tissue is promoted by increased levels of growth factors, emphasizing the role of growth factors in resolution [50, 51].”
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 2×
“Studies on AD brains and data from animal studies show the presence of activated glial cells around the plaques [5, 11, 12].”
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“Early evidence of a role for inflammation in AD pathogenesis originates from epidemiological studies, showing reduced prevalence of AD in patients under treatment with non-steroidal anti-inflammatory drugs (NSAIDs) ([26], see [27]).”
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081880 · Cited by 908 · cited 2×
“DHA and EPA are precursors for the SPMs resolvin, maresin, and neuroprotectin [49, 63], which have been shown to stimulate phagocytosis and down-regulate inflammation.”
McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Self-citationCombs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721
Cited by
Polyunsaturated fatty acids and their metabolites in brain function and disease
Bazinet, R. P., & Layé, S. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3820 · Cited by 1,605
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Omega-3 long-chain polyunsaturated fatty acids and aquaculture in perspective
Tocher, D. R. (2015) · Aquaculture · doi:10.1016/j.aquaculture.2015.01.010 · Cited by 769
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
Docosahexaenoic Acid and Cognition throughout the Lifespan
Weiser, M., Butt, C., & Mohajeri, M. (2016) · Nutrients · doi:10.3390/nu8020099 · Cited by 400
Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases
Sun, G. Y., Simonyi, A., Fritsche, K. L., Chuang, D. Y., Hannink, M., Gu, Z., Greenlief, C. M., Yao, J. K., Lee, J. C., & Beversdorf, D. Q. (2018) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.03.006 · Cited by 309
Food for thought: how nutrition impacts cognition and emotion
Spencer, S. J., Korosi, A., Layé, S., Shukitt-Hale, B., & Barrientos, R. M. (2017) · npj Science of Food · doi:10.1038/s41538-017-0008-y · Cited by 268
The human microglial HMC3 cell line: where do we stand? A systematic literature review
Dello Russo, C., Cappoli, N., Coletta, I., Mezzogori, D., Paciello, F., Pozzoli, G., Navarra, P., & Battaglia, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1288-0 · Cited by 265
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204
Self-citationImpact of dietary fats on brain functions
Chianese, R., Coccurello, R., Viggiano, A., Scafuro, M., Fiore, M., Coppola, G., Operto, F. F., Fasano, S., Laye, S., Pierantoni, R., et al. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171017102547 · Cited by 159
Fan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015) · Brain · doi:10.1093/brain/awv288 · Cited by 135
Key Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation
Caldeira, C., Cunha, C., Vaz, A. R., Falcão, A. S., Barateiro, A., Seixas, E., Fernandes, A., & Brites, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00277 · Cited by 117
“Aβ1–42 peptide was diluted in DMEM-Ham’s F12 culture medium to a stock concentration of 111 µM and allowed to incubate for 24 h at 37◦C to preaggregate the peptides, as formerly indicated (Hjorth et al., 2013).”
MethodAPP Function and Lipids: A Bidirectional Link
Grimm, M. O. W., Mett, J., Grimm, H. S., & Hartmann, T. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00063 · Cited by 104
Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis
Yassine, H. N., Feng, Q., Azizkhanian, I., Rawat, V., Castor, K., Fonteh, A. N., Harrington, M. G., Zheng, L., Reed, B. R., DeCarli, C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1924 · Cited by 94
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Lepiarz-Raba, I., Gbadamosi, I., Florea, R., Paolicelli, R. C., & Jawaid, A. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00382-w · Cited by 90
Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism
Bonfili, L., Cuccioloni, M., Gong, C., Cecarini, V., Spina, M., Zheng, Y., Angeletti, M., & Eleuteri, A. M. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.01.025 · Cited by 69
He, S., Xu, Z., & Han, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00803-6 · Cited by 62
Direct and indirect effects of lipids on microglia function
Leyrolle, Q., Layé, S., & Nadjar, A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134348 · Cited by 50
Role of metabolic programming in the modulation of microglia phagocytosis by lipids
Nadjar, A. (2018) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.07.006 · Cited by 49
Souza, C. M. M., de Lima, D. C., Bastos, T. S., de Oliveira, S. G., Beirão, B. C. B., & Félix, A. P. (2019) · Animal Science Journal · doi:10.1111/asj.13294 · Cited by 31
Bazan, N. G. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8897-0 · Cited by 15
Metabolic control of microglia
Garcia-Segura, M. E., Pluchino, S., & Peruzzotti-Jametti, L. (2024) · Advances in Neurobiology · doi:10.1007/978-3-031-55529-9_34 · Cited by 4
Metadata
- Authors
- Hjorth, E., Zhu, M., Toro, V. C., Vedin, I., Palmblad, J., Cederholm, T., Freund-Levi, Y., Faxen-Irving, G., Wahlund, L.-O., Basun, H., Eriksdotter, M., & Schultzberg, M.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2013-05-21
- Volume
- 35
- Issue
- 4
- Pages
- 697-713
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2157010753
- Cited by
- 229
- References
- 19
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.